Page 66 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $5.54
52wk Low $1.11 Eledon Pharmaceuticals, Inc ELDN $4.01
19900 MacArthur Boulevard
Irvine, CA 92612

(USD - in millions) eledon.com
Market Cap 246.7
Enterprise 169.0
Basic Shares Out. 59.74 COMPANY OVERVIEW
Float 46.29
Institutional Holdings 20.46% Detailed Analysis:Channelchek.com
Short Interest 0.96 Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company
Avg. 90-Day Volume 0.34 that is developing immune-modulating therapies for the management
and treatment of life-threatening conditions. The Company’s lead
investigational product is tegoprubart, an anti-CD40L antibody with high
affinity for the CD40 Ligand, a well-validated biological target that has
EPS Data broad therapeutic potential. The central role of CD40L signaling in both
adaptive and innate immune cell activation and function positions it as
2022 2023 2024 an attractive target for non-lymphocyte depleting, immunomodulatory
CQ1 (0.69) (0.75) (0.34) therapeutic intervention. The Company is building upon a deep
CQ2 (0.65) (0.40) (1.06) historical knowledge of anti-CD40 Ligand biology to conduct preclinical
and clinical studies in kidney allograft transplantation,
CQ3 (0.73) (0.35) (0.32) xenotransplantation, and amyotrophic lateral sclerosis (ALS).
CQ4 (0.68) (0.29) (0.28)
CY (2.75) (1.64) (1.16) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.85
ROE (ttm) -25.36
Debt-to-Total Cap. (mrq) 0.65
Fiscal Year End 31-Dec

19900 MacArt Irvine CA 92612

Key Executives
CEO: Gros, David-Alexandre
CFO: Little, Paul
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures